ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

ImmunityBio, Inc.NASDAQ: IBRX

Operating Expenses · Q3 FY2026 · quarter ended Sep 2026

Operating expenses growth accelerates

Q3 FY2026 operating expenses of $125.54M rose 50.2% year over year, ahead of the +32.9% change in trailing-twelve-month operating expenses. Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at +1.6% a year.

Context

  • Operating expenses amounted to 325.3% of revenue in FY2025, down 2108.9 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +50.2% holds above the trailing-twelve-month pace of +32.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$125.54M+11.5% QoQ
Last fiscal yearDec 2025
$368.56M+2.7% YoY
LTMSep 2026
$450.66M+32.9% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+50.2%——
1 year+2.7%——
3-year CAGR+1.6%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
368.56M USD
Year-over-year change
+2.7%
4-year CAGR
+2.7%

Operating Expenses vs competitors

How IBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +32.9% is the 2nd highest of 11, against a peer median of -1.3%.
  • Operating expenses amounts to 246.8% of revenue for IBRX, versus a peer median of 133.0%.
IBRX Competitors
Operating Expenses for IBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€3.77B EUR+18.8%+18.2%142.6%
MRNAModerna, Inc.LTM Sep 2026$3.64B USD-2.4%+0.9%144.0%
LEGNLegend Biotech CorporationLTM Sep 2026$740.02M USD-0.1%+14.3%54.5%
VIRVir Biotechnology, Inc.LTM Mar 2026$641.93M USD+299.5%+48.0%980.1%
IBRXImmunityBio, Inc.LTM Sep 2026$450.66M USD+32.9%+1.6%246.8%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$432.13M USD-11.1%+7.0%114.0%
IMCRImmunocore Holdings plcLTM Mar 2026$410.51M USD+8.6%+21.4%106.4%
IMTXImmatics N.V.LTM Mar 2026€250M EUR+22.1%+17.2%670.3%
NKTXNkarta, Inc.LTM Mar 2026$113.97M USD-13.7%-2.0%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$112.97M USD-32.5%-15.4%—
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$28.55M USD-83.6%-4.9%123.4%
Peer median (excluding IBRX) —-1.3%+10.6%133.0%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue934K240K622K14.75M113.29M
Cost of Revenue0000753K
Gross Profit934K240K622K14.75M112.54M
Gross Margin100.0%100.0%100.0%100.0%99.3%
Research & Development195.96M248.15M232.37M190.14M207.88M
Selling, General & Admin135.26M102.71M129.62M168.78M147.18M
Operating Expenses331.21M351.54M362.87M358.93M368.56M
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
EBITDA(320.75M)(351.88M)(478.66M)(264.43M)(223.56M)
EBITDA Margin-34341.8%-146617.1%-76955.5%-1793.4%-197.3%
Operating Income(330.28M)(351.3M)(362.25M)(344.18M)(256.03M)
Operating Margin-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
Interest Income836K2.71M863K2.4M6.7M
Interest Expense14.85M47.15M86.72M131.66M112.53M
Other Income / Expenses(19.56M)(65.99M)(221.64M)(69.46M)(95.58M)
Income Before Tax(349.84M)(417.29M)(583.89M)(413.65M)(351.61M)
Pre-Tax Margin-37456.0%-173869.2%-93873.3%-2805.3%-310.4%
Income Tax Expense9K34K(40K)0(135K)
Net Income(346.79M)(416.57M)(583.2M)(413.56M)(351.4M)
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (Basic)(0.89)(1.04)(1.15)(0.59)(0.38)
EPS (Diluted)(0.89)(1.04)(1.15)(0.62)(0.38)
Weighted Avg Shares389.23M399.9M508.64M697.31M919.86M
Weighted Avg Shares (Diluted)389.23M399.9M508.64M700.44M919.86M

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.